Skip to content


Gattex, Revestive (teduglutide) is a protein pharmaceutical. Teduglutide was first approved as Gattex on 2012-08-30. It is used to treat short bowel syndrome in the USA. It has been approved in Europe to treat malabsorption syndromes. The pharmaceutical is active against glucagon-like peptide 2 receptor. Gattex's patents are valid until 2025-11-01 (FDA).
Trade Name Revestive
Common Name Teduglutide
Indication malabsorption syndromes, short bowel syndrome
Drug Class Peptides: GLP peptide analogs
Get full access now